Osr Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 21-12-2024
- Paid Up Capital ₹ 0.10 M
as on 21-12-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.46 M
as on 21-12-2024
- Revenue 5.11%
(FY 2017)
- Profit 133.47%
(FY 2017)
- Ebitda 59.45%
(FY 2017)
- Net Worth 56.89%
(FY 2017)
- Total Assets -17.24%
(FY 2017)
About Osr Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.46 M.
Aarti Batra and Siddharth Dua serve as directors at the Company.
- CIN/LLPIN
U24232DL2011PTC212337
- Company No.
212337
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jan 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Osr Pharmaceuticals Private Limited offer?
Osr Pharmaceuticals Private Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Calcium Tablet, Calcium Citrate Malate Tablet, Clonazepam Tablet, Paroxetine Tablets, Antidepressant Tablet, Common Disease Medicines, Pharmaceutical Capsules, Blood Pressure Medicine.
Who are the key members and board of directors at Osr Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aarti Batra  | Director | 07-Jan-2011 | Current |
| Siddharth Dua | Director | 03-Oct-2011 | Current |
Financial Performance of Osr Pharmaceuticals.
Osr Pharmaceuticals Private Limited, for the financial year ended 2017, experienced modest growth in revenue, with a 5.11% increase. The company also saw a substantial improvement in profitability, with a 133.47% increase in profit. The company's net worth Soared by an impressive increase of 56.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Osr Pharmaceuticals?
In 2017, Osr Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 02 Feb 2023 | ₹0.46 M | Open |
How Many Employees Work at Osr Pharmaceuticals?
Unlock and access historical data on people associated with Osr Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Osr Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Osr Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
